Following the Herbalife (HLF +0.3%) story feels like watching an endless tetherball match. Earlier today Janney cut the stock to Neutral, essentially saying it's a lose-lose position on either side, but D.A. Davison analyst Timothy Ramey disagrees. He feels the stock is a "compelling buy" at any price below $70, despite all the criticism. Ramey said Thursday's presentation by HLF was solid, and the company "thoroughly and completely silenced the noise of its critics." At some point, the analysis on someone's side of this debate is bound to stumble, and when it does they're going to really get served.